Theravance Biopharma, Inc.

NasdaqGM:TBPH 주식 보고서

시가총액: US$472.6m

Theravance Biopharma 미래 성장

Future 기준 확인 5/6

Theravance Biopharma은 연간 수입과 매출이 각각 73.1%와 20.3% 증가할 것으로 예상되고 EPS는 연간 74%만큼 증가할 것으로 예상됩니다.

주요 정보

73.1%

수익 성장률

74.0%

EPS 성장률

Pharmaceuticals 수익 성장23.7%
매출 성장률20.3%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트13 Nov 2024

최근 미래 성장 업데이트

Recent updates

With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For

Nov 12
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For

We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Jul 16
We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Feb 05
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Theravance to purchase $95M of ordinary shares

Sep 28

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma announces $250M capital return program

Sep 19

Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M

Aug 04

Theravance: All-Round Failure

Mar 10

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study

Jun 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

수익 및 매출 성장 예측

NasdaqGM:TBPH - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026104-369N/A5
12/31/2025103462N/A5
12/31/202473-38-10N/A5
9/30/202463-49-12-11N/A
6/30/202462-46-10-9N/A
3/31/202462-45-18-17N/A
12/31/202357-55-29-27N/A
9/30/202355-61-152-150N/A
6/30/202351-68-172-170N/A
3/31/202349-75-173-172N/A
12/31/202251-93-188-187N/A
9/30/202252-136-106-105N/A
6/30/202252-196-131-129N/A
3/31/202254-226-166-164N/A
12/31/202155-265-211-208N/A
9/30/202159-266-235-230N/A
6/30/202164-264-267-262N/A
3/31/202166-275-273-265N/A
12/31/202072-295-257-250N/A
9/30/202083-285-257-250N/A
6/30/202077-270-222-217N/A
3/31/202088-247-215-212N/A
12/31/201973-236-241-238N/A
9/30/201960-221-229-226N/A
6/30/201960-222-236-230N/A
3/31/201957-223-250-244N/A
12/31/201860-216-120-113N/A
9/30/201849-252-111-105N/A
6/30/201841-260N/A-118N/A
3/31/201821-285N/A-101N/A
12/31/201715-285N/A-201N/A
9/30/201717-266N/A-185N/A
6/30/201731-233N/A-135N/A
3/31/201733-214N/A-123N/A
12/31/201649-191N/A-99N/A
9/30/201647-168N/A-105N/A
6/30/201638-182N/A-124N/A
3/31/201640-182N/A-139N/A
12/31/201542-182N/A-169N/A
9/30/201540-202N/A-178N/A
6/30/201535-209N/A-182N/A
3/31/201531-219N/A-187N/A
12/31/201412-237N/A-175N/A
9/30/201410-217N/A-168N/A
6/30/20144-203N/A-164N/A
3/31/20141-184N/A-137N/A
12/31/20130-156N/A-121N/A

애널리스트 미래 성장 예측

수입 대 저축률: TBPH 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: TBPH (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: TBPH 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: TBPH 의 수익(연간 20.3% ) US 시장( 9% 보다 빠르게 성장할 것으로 예상됩니다. 9% 연간).

고성장 수익: TBPH 의 수익(연간 20.3% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: TBPH 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견